

Programme IQWiG in dialogue

Benefit assessment in studies with allowed treatment switching

Moderation: Prof. Dr. Ralf Bender

10.00 - 10.15	Welcoming address
10.15 - 10.45	The ethical dimensions of studies with allowed treatment switching Professor Dr Daniel Strech, Hanover Medical School (MHH)
10.45 - 11.15	Criteria for treatment switching in oncological studies Professor Dr Bernhard Wörmann, German Society of Haematology and Oncology (DGHO)
11.15 - 11.45	The role of the Federal Institute for Drugs and Medical Devices (BfArM) in the planning, authorization and acceptance of clinical studies and their results in oncology PD Dr Thomas Sudhop, BfArM
11.45 - 12.30	Discussion
12.30 - 13.15	Lunch break
13.15 - 13.45	Evaluation of treatment switching in the Institute's assessments Dr Volker Vervölgyi, IQWiG
13.45 - 14.15	Methoden zur Schätzung der Überlebenszeit nach Behandlungswechsel in der Onkologie – Überblick und praktische Hinweise Dr Norbert Holländer, Novartis
14.15 - 14.45	Methods to estimate survival time after treatment switching in oncology – overview and practical considerations Professor Dr Ulrich Mansmann, Ludwig Maximilians University (LMU) Munich
14.45 - 15.30	Discussion
15.30 - 16.00	Conclusion of the meeting with coffee and cake

Location: KOMED, Im Mediapark 6 - Haus 6, D-50670 Köln